Author

Fatih Köse

Observed names: F. Kose, Fatih Kose, Fatih KÖSE, Köse, Fatih

Institution: Başkent University

Observed institutions: Tekirdağ Namık Kemal University, Sivas Cumhuriyet Üniversitesi, Ministry of Health, Başkent University

ORCID: 0000-0001-7493-7494

Observed ORCID: 0000-0001-7493-7494

OpenAlex ID: A5068387620

Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study.

2025 · Neil Howard Segal, Maria Passhak, et al. · Journal of Clinical Oncology · 9

Multi-institutional validation of the ESMO-ESGO-ESTRO consensus conference risk grouping in Turkish endometrial cancer patients treated with comprehensive surgical staging

2020 · Melis Gultekin, Ozan Cem Guler, et al. · Journal of Obstetrics and Gynaecology · 9

Baytarnâmelerde Büyü Ve Tilsimlar

2022 · Fatih KÖSE · Bandırma Onyedi Eylül Üniversitesi Sosyal Bilimler Araştırmaları Dergisi · 2

Preimplantation genetic testing (PGT-M) awareness in BRCA-positive individuals in Türkiye: a dual physician–patient survey

2026 · Irfan Cicin, Taha Bahsi, et al. · Scientific Reports · 1

Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

2025 · Safa Can Efil, Fatih Kus, et al. · Cancers · 1

Pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer: longer-term follow-up from the randomised, double-blind, placebo-controlled, phase 3 KEYNOTE-966 trial

2026 · Makoto Ueno, Changhoon Yoo, et al. · EClinicalMedicine

354P Tailoring adjuvant concurrent chemoradiotherapy or radiotherapy in resected biliary tract cancers using individualized treatment effect modelling (TOG/GI-SAFRADJU-2601-AI)

2026 · E. Akkus, M. Kayaalp, et al. · Annals of Oncology

Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA–guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC).

2026 · Joaquim Bellmunt, Shilpa Gupta, et al. · Journal of Clinical Oncology

Investigating the feasibility of cascade genetic testing for BRCA1/2 in Türkiye: physicians' practices, barriers, and solutions

2026 · Irfan Cicin, Tulay Kus, et al. · European Journal of Cancer Care

663TiP BNT323-01: A phase III trial of trastuzumab pamirtecan (HER2 ADC) versus investigator’s choice of chemotherapy in pretreated patients with HER2-expressing recurrent endometrial cancer (EC)

2025 · J-H. Kim, H. Dahlstrand, et al. · Annals of Oncology

1756 İstanbul Yangını

2019 · Köse, Fatih · Mevzu – Sosyal Bilimler Dergisi

000181: Brca1/brca2 Mutations in Primary Ovarian Cancer Patients

2005 · B. Aktas, M. Gultekin, et al. · International Journal of Gynecological Cancer

Works count: 13

Citation count: 22

H-index: 2

I10-index: